Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REGN
DateTimeSourceHeadlineSymbolCompany
05/08/20245:00AMGlobeNewswire Inc.Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 WeeksNASDAQ:REGNRegeneron Pharmaceuticals Inc
05/06/20243:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
05/06/20243:05PMGlobeNewswire Inc.Regeneron Announces Investor Conference PresentationsNASDAQ:REGNRegeneron Pharmaceuticals Inc
05/02/20245:30AMGlobeNewswire Inc.Regeneron Reports First Quarter 2024 Financial and Operating ResultsNASDAQ:REGNRegeneron Pharmaceuticals Inc
04/29/20246:00AMGlobeNewswire Inc.EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal DiseasesNASDAQ:REGNRegeneron Pharmaceuticals Inc
04/25/20246:00AMGlobeNewswire Inc.Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple DiseasesNASDAQ:REGNRegeneron Pharmaceuticals Inc
04/24/20249:05AMGlobeNewswire Inc.Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCONASDAQ:REGNRegeneron Pharmaceuticals Inc
04/22/20244:54PMGlobeNewswire Inc.Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)NASDAQ:REGNRegeneron Pharmaceuticals Inc
04/16/20246:18AMIH Market NewsEricsson Soars with 66% Net Profit Growth; Live Nation Under Antitrust Scrutiny in US, and More NewsNASDAQ:REGNRegeneron Pharmaceuticals Inc
04/11/20246:24AMIH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:REGNRegeneron Pharmaceuticals Inc
04/07/20243:00PMGlobeNewswire Inc.Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple MyelomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
04/01/20243:05PMGlobeNewswire Inc.Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024NASDAQ:REGNRegeneron Pharmaceuticals Inc
03/25/20246:00AMGlobeNewswire Inc.Regeneron Provides Update on Biologics License Application for OdronextamabNASDAQ:REGNRegeneron Pharmaceuticals Inc
03/12/202410:55PMPR Newswire (US)High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical OptimizationNASDAQ:REGNRegeneron Pharmaceuticals Inc
03/12/20248:30PMGlobeNewswire Inc.High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical OptimizationNASDAQ:REGNRegeneron Pharmaceuticals Inc
03/11/20246:00AMGlobeNewswire Inc.Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High CholesterolNASDAQ:REGNRegeneron Pharmaceuticals Inc
03/08/20246:00AMGlobeNewswire Inc.EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The LancetNASDAQ:REGNRegeneron Pharmaceuticals Inc
03/05/20243:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
03/05/20243:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
03/01/20243:14PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/28/20243:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/28/20243:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/28/20243:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/26/20243:34PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/26/20243:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/26/20243:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/26/20243:07PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/26/20243:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/26/20242:25PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/23/20243:04PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:REGN

Your Recent History

Delayed Upgrade Clock